IL-STATS-PERFORM
7.10.2019 13:02:09 CEST | Business Wire | Press release
Today, Stats Perform , the revolutionary leader in sports AI and data, and Control Risks , the leading specialist risk consultancy, announce a unique partnership to bring best-in-class comprehensive sports integrity solutions to the market.
Through Stats Perform’s Integrity Unit, sports industry stakeholders such as rights holders, International Federations and Governing Bodies will be able to access Control Risks’ global investigative capabilities to help drive out corruption and match-fixing. Integrity units and compliance departments will have access to a full range of solutions, including forensic accounting, data analytics and traditional investigative capabilities, to manage risk or conduct investigations.
The partnership will combine Stats Perform’s offering across prevention, detection and investigation with Control Risks’ global investigative practice and experience in building resilient and compliant governance programmes. Together, they will help stakeholders ensure their integrity, anti-doping and compliance programmes are fit-for-purpose, while protecting the long-term value of their brands.
Furthermore, global sport stakeholders will be able to utilise the full suite of services the partnership has to offer, whether it is a team requiring due diligence on a potential investor, sponsor or new signing, or a business looking to partner with a new league or competition. The partnership will enable sports stakeholders to manage both sporting integrity and business risks in one place.
Nick Allan , CEO of Control Risks, said: “We are delighted to announce this exciting new partnership with Stats Perform to help the sports industry in its desire to combat the threats to its integrity posed by corruption and match-fixing. Our global investigations capabilities will enable all stakeholders, to be able to call on our support as part of their contract with Stats Perform.”
Mike Perez , COO of Stats Perform, said: “As the sports industry goes through a data revolution, our existing integrity services will benefit from complementary investigative capabilities to identify, investigate and respond to threats. We are very pleased to move forward with Control Risks who have the global capabilities to match our aspirations.”
Jonny Gray , Global Head of Sport at Control Risks, said: “This is a very exciting development as the sports industry looks for comprehensive support to combat existential threats to its integrity, trust and value. It gives Stats Perform’s clients the opportunity for a complete integrity solution.”
Jake Marsh , Head of Integrity at Stats Perform, said: “Sports stakeholders face a variety of governance and integrity challenges. Our role is not simply to help them identify and mitigate risk, but to assist in investigation and response. Our partnership with Control Risks helps us do that and provide a better, more complete service to our clients.”
About Control Risks
Control Risks is a specialist risk consulting firm that helps create secure, compliant and resilient organizations. We believe that taking risks is essential to success, so we provide the insight and intelligence you need to realize opportunities and grow.
Our experts across 34 offices bring experience in prosecution and law enforcement, accounting, management consulting, regional business intelligence, forensic technology and cyber security to advise the world’s largest multinational companies on major regulatory issues, conduct complex cross-border investigations and build robust compliance programs.
Learn more at www.controlrisk.com/sport
About Stats Perform
Stats Perform collects the richest sports data in the world and transforms it through revolutionary artificial intelligence (AI) to unlock the most in-depth insights for media and technology, betting and team performance. With company roots dating back almost 40 years, Stats Perform embraces and solves the dynamic nature of sport – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. As the leading sports data and AI company, Stats Perform works with the top global sports media, tech companies, sportsbooks, teams and leagues.
For more information, visit StatsPerform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom